Pro-Dex: Still A Buy, But Don't Chase

Pro-Dex reported nice Q1 sales of $19.9 million, which is up 14.6% YoY. Their largest customer contract now runs through December 2028, reducing potential near-term risks in that sense. Also, their APM acquisition gives them more control over their supply chain and brings some potential aerospace/defense optionality.

Seeking Alpha • May 15, 2026

Pro-Dex, Inc. Announces Fiscal 2026 Third Quarter and Nine Month Results

IRVINE, CA / ACCESS Newswire / April 30, 2026 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 third quarter ended March 31, 2026.

Accesswire • Apr 30, 2026

Pro-Dex, Inc. Announces Acquisition of Advanced Precision Machining

IRVINE, CA / ACCESS Newswire / February 12, 2026 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced that on February 9, 2026 it completed its acquisition of Advanced Precision Machining LLC, ("APM"), formerly operated as Advanced Precision Machining, Inc., a manufacturing facility located in Costa Mesa, Calif.

Accesswire • Feb 12, 2026

Pro-Dex, Inc. Announces Fiscal 2026 Second Quarter and Six-Month Results

IRVINE, CA / ACCESS Newswire / January 29, 2026 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 second quarter ended December 31, 2025.

Accesswire • Jan 29, 2026

Pro-Dex: A Niche Surgical Tools Microcap Trading At A Discount

Pro-Dex manufactures powered surgical instruments for orthopedic, CMF, and thoracic procedures. This means that PDEX effectively combines OEM programs with a smaller catalog of industrial offerings. However, PDEX's revenue today remains highly concentrated. A single customer drives roughly 78% of sales.

Seeking Alpha • Jan 17, 2026

Pro-Dex Valuation Is Attractive Despite Customer Risk

Pro-Dex Inc. is a specialized surgical device manufacturer with strong growth, efficient capital allocation, and high customer concentration risk. PDEX trades at ~16x recurrent earnings, which is fair and attractive for a small, non-concentrated position given its quality and growth prospects. Customer concentration remains the key risk, but contract renewals, sticky relationships, and secular healthcare tailwinds support continued growth.

Seeking Alpha • Jan 8, 2026

Pro-Dex, Inc. Announces Contract Extension With Largest Customer

IRVINE, CA / ACCESS Newswire / December 19, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced that on December 17, 2025, it executed a contract amendment with its largest customer for an additional three years.

Accesswire • Dec 19, 2025

Pro-Dex, Inc. Announces Fiscal 2026 First Quarter Results

IRVINE, CA / ACCESS Newswire / October 30, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 first quarter ended September 30, 2025.

Accesswire • Oct 30, 2025

Pro-Dex, Inc. (PDEX) Q1 Earnings and Revenues Top Estimates

Pro-Dex, Inc. (PDEX) came out with quarterly earnings of $0.62 per share, beating the Zacks Consensus Estimate of $0.5 per share. This compares to earnings of $0.75 per share a year ago.

Zacks Investment Research • Oct 30, 2025

Pro-Dex, Inc. Announces Clarification Related to Trading Symbol

IRVINE, CA / ACCESS Newswire / October 16, 2025 / PRO-DEX, INC. (NasdaqCM:PDEX) is issuing this press release in an effort to help avoid any confusion in the marketplace between the common stock of Pro-Dex, Inc., which trades on the Nasdaq Capital Market under the symbol PDEX, and Polkadex, which to Pro-Dex, Inc.'s understanding trades on certain crypto exchanges (and possibly on certain other platforms) under the same symbol.

Accesswire • Oct 16, 2025